Evidence map›Paper›PMID 22438931›Full record

Trial reportPloS one2012

Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure.

Benjamin W Van Tassell, Ross A Arena, Stefano Toldo, Eleonora Mezzaroma, Tania Azam, Ignacio M Seropian, Keyur Shah, Justin Canada, Norbert F Voelkel, Charles A Dinarello and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01300650 (Pilot Study of the Safety and Efficacy of Anakinra), which is not on this map. Cited by 115 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 1 pooled it
42.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01300650 phase1 / phase2completednot on this map

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2011 to 2011Enrolled11ConditionsHeart FailureArmsAnakinra
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 1 synthesis or guideline pooled it, 221 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure.Medicine and science in sports and exercise · 2018
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Benjamin W Van TassellSchool of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States of America. bvantassell@vcu.edu
Ross A Arena
Stefano Toldo
Eleonora Mezzaroma
Tania Azam
Ignacio M Seropian
Keyur Shah
Justin Canada
Norbert F Voelkel
Charles A Dinarello
Antonio Abbate
Virginia Commonwealth University · USUniversity of Colorado Boulder · USUniversity of New Mexico · US

Funding

Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR031990 · NCRR · VIRGINIA COMMONWEALTH UNIVERSITY · PI CLORE, JOHN N. · 2010 to 2011
$7.7M
Center for Clinical and Translational ResearchKL2TR000057 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2014
$1.4M
NCATS NIH HHS KL2 TR000057NCATS NIH HHS UL1 TR000058NCRR NIH HHS UL1 RR031990NCRR NIH HHS UL1RR031990
6 · The paper itself

Abstract

backgroundHeart failure (HF) is a complex clinical syndrome characterized by impaired cardiac function and poor exercise tolerance. Enhanced inflammation is associated with worsening outcomes in HF patients and may play a direct role in disease progression. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that becomes chronically elevated in HF and exerts putative negative inotropic effects. METHODS AND

resultsWe developed a model of IL-1β-induced left ventricular (LV) dysfunction in healthy mice that exhibited a 32% reduction in LV fractional shortening (P<0.001) and a 76% reduction in isoproterenol response (P<0.01) at 4 hours following a single dose of IL-1β 3 mcg/kg. This phenotype was reproducible in mice injected with plasma from HF patients and fully preventable by pretreatment with IL-1 receptor antagonist (anakinra). This led to the design and conduct of a pilot clinical to test the effect of anakinra on cardiopulmonary exercise performance in patients with HF and evidence of elevated inflammatory signaling (n = 7). The median peak oxygen consumption (VO(2)) improved from 12.3 [10.0, 15.2] to 15.1 [13.7, 19.3] mL · kg(-1) · min(-1) (P = 0.016 vs. baseline) and median ventilator efficiency (V(E)/VCO(2) slope) improved from 28.1 [22.8, 31.7] to 24.9 [22.9, 28.3] (P = 0.031 vs. baseline).

conclusionsThese findings suggest that IL-1β activity contributes to poor exercise tolerance in patients with systolic HF and identifies IL-1β blockade as a novel strategy for pharmacologic intervention.

trial registrationClinicalTrials.gov NCT01300650.

Indexed as

AdultAnimalsBiomarkersC-Reactive ProteinCytokinesDisease Models, AnimalExercise TestExercise ToleranceFemaleHeart Failure, SystolicHumansInflammation MediatorsInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinMaleMiceBiomarkersC-Reactive ProteinCytokinesInflammation MediatorsInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinRecombinant Proteins

Identifiers

PMID22438931
PMCPMC3306393
OpenAlexW2100934097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.